Sugi Predict

Sugi Predict / Compounds / SCHEMBL10067279

SCHEMBL10067279

SCHEMBL10067279

CC(C)n1cc(-c2nc3c4cccnc4c4ncccc4c3[nH]2)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ POLB P06746 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ PTGES O14684 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ TDO2 P48775 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067304 0.86 PDE4B (0.51) CA12CA1CA2CA9ALDH1A1
SCHEMBL28295235 0.77 KDM4E (0.55) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL10067264 0.77 PDE4A (0.45) CA12CA1CA2CA9ALDH1A1
SCHEMBL10067294 0.76 HTR6 (0.43) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL21180300 0.75 GAA (0.50) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL10067286 0.75 KMT2A (0.42) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL14579767 0.74 MAP4K4 (0.47) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL5323937 0.73 MAP4K4 (0.52) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL30171053 0.73 MAP4K4 (0.52) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL21180250 0.71 PTGES (0.49) ALDH1A1MAPTKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
WO-2010102393-A1 2-INDOLYL IMIDAZO [4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE TO INHIBIT ANGIOGENESIS LORUS THERAPEUTICS INC. (CA) 2010-09-16 — — WO disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 CA12 4237/4885CA1 2727/4885CA2 2660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.